Jacob White

[email protected]

LATEST

AstraZeneca Launches $1.5-Bn Cost-Savings Plan 
By

By
AstraZeneca has announced a $1.5-billion cost-savings plan over three years designed to support capital flow in the company’s existing business and therapy areas. The company highlighted the plan as part…

BI, Sino Biopharmaceutical in $7.4-Bn for ADCs, T-Cell Engagers 
By

By
Boehringer Ingelheim (BI) and Sino Biopharmaceutical, a Hong Kong-based bio/pharmaceutical company and its subsidiaries (collectively, SBP Group), have formed a multi-program option and license agreement for antibody-drug conjugate (ADC) and…

Supplier News: Cambrex, Kindeva, Alcami, Catalent & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Cambrex, Aptar Pharma, Kindeva, Alcami, Catalent, DFE Pharma, and Codis.   Chemicals/Chemical API Manufacturing * Cambrex Breaks Ground on $120-M Small-Molecule, Peptide ExpansionFormulation Development/Drug…

Global Briefs: Fresenius and AbbVie 
By

By
A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring AbbVie and Fresenius. Highlights below.    For the latest news roundup on small and Emerging Pharma companies, see Biotech…

Biotech Briefs: Agios, Evommune, Rhythm Pharmaceuticals & More 
By

By
The latest from small and Emerging Pharma companies featuring Agios Pharmaceuticals, Evommune, Rhythm Pharmaceuticals, and T-Therapeutics  For news on the on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. …

Protacs & Molecular Glue Degraders: Market Contenders or Not?
By

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

New DCAT Member Company Alert
By

By
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…

Lilly Breaks Ground on $5-Bn Mfg Facility in the US 
By

By
Eli Lilly and Company has broken ground on a new $5-billion manufacturing facility in Goochland County, Virginia, west of Richmond, Virginia, which will produce active pharmaceutical ingredients (APIs) and finished…

Gilead To Acquire PepStar’s Oral, Macrocyclic Peptide Anti-Inflammatory Drug for $1.3 Bn 
By

By
Gilead Sciences has agreed to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, an inflammatory macrocyclic peptide inhibitor, from PepStar Therapeutics, a clinical-stage bio/pharmaceutical company, for $1.275 billion. The…

Supplier News: Lonza, CordenPharma, Aptar, Stevanato & Upperton 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Upperton Pharma Solutions and CordenPharma.   Biologics Manufacturing * Lonza To Expand Bioconjugation Mfg FacilityFormulation Development/Drug Product Manufacturing * Upperton, MVIC in Inhalation Drug-Delivery CollaborationPackaging *…